- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Developing Strategies to Drive Value in Mental Health Care, Part 3
Leadership from the Innovation & Value Initiative, along with experts in mental health and a representative from employer purchasing group, discuss strategies for creating value-based decisions in mental health coverage.
In the latest Matters in Managed Care webinar, experts discussed the current state of mental health care, including the growing consensus on the need for change, strategies to provide high value care, and opportunities for collaboration among payers and other healthcare stakeholders.
The speakers highlighted common challenges for employers and payers regarding coverage for mental health care; discussed common definitions of value for payers, employers, and people with lived experience; shared strategies to incentivize high-value interventions for mental health care; and identified opportunities for future collaboration.
The speakers were:
- Schroeder Stribling, MSW, president and CEO, Mental Health America
- Michael Thompson, president and CEO, National Alliance of Healthcare Purchaser Coalitions
- Jennifer Bright, MPA, executive director, Innovation and Value Initiative
- Kevin Ronneberg, MD, vice president and associate medical director, HealthPartners
In segment 3, they discussed existing incentives in mental health care and whether or not they make sense.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Quantitative Magnetic Resonance Outcomes Suggest Gene Therapy Slows DMD Progression
May 14th 2025Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.
Read More
